Medication info
Nodiarex Tablet (Gliclazide)

Nodiarex Tablet (Gliclazide)

Prescription medicationTabletOral
Ingredient · strength
Gliclazide›80mg / 1 tablet
Manufacturer / importer
(Samnam Pharmaceutical Co., Ltd.)
Appearance
White round tablets
Packaging
30 tablets/bottle, 500 tablets/bottle
Approval status
Active

MFDS item code 199401029 · Notified 1994.12.05 · Insurance code 653700120

Summary

Main use
Treatment of type 2 diabetes mellitus
Who takes it
Adults
Adult dose
Adults: Start with 40~80mg of gliclazide per day, administered orally in 1~2 divided doses. Thereafter, to optimally control the patient's blood glucose level, the dose may be increased according to the patient's condition up to a maximum of 320mg per day, administered in 2 divided doses. Do not exceed 160mg per dose. The dose must be adjusted according to the patient's condition. Additional treatment may be required for obese patients or patients who do not respond adequately to this medicine alone. * Initial dose The recommended initial dose is 30mg per day. - If glycemic control is satisfactory, maintain this dose as the maintenance dose. - If glycemic control is unsatisfactory, the dose may be gradually increased to 60, 90, and 120mg per day at intervals of at least 1 month. If blood glucose has not decreased after 15 days of treatment, increase the dose from the end of the second week of treatment. Do not exceed the maximum dose of 120mg per day. * Switching from gliclazide 80mg to gliclazide modified-release tablets 30mg: In patients stabilized on gliclazide 80mg, administer the medicine according to the principle that "gliclazide 80mg = gliclazide modified-release tablets 30mg." * Switching from another oral hypoglycemic agent to gliclazide modified-release tablets 30mg: Consider the dose and half-life of the previous hypoglycemic agent. In general, switching can be done without any transitional washout period. Start this medicine at 30mg per day, then gradually increase the dose according to each patient's metabolic response as described in the "Initial dose" section. For patients switching from a sulfonylurea hypoglycemic agent with a long half-life, a washout period of several days is required to prevent the risk of hypoglycemia due to the additive effects of the two medicines. * Use in combination with other oral hypoglycemic agents This medicine may be used in combination with biguanides, α-glucosidase inhibitors, or insulin. * Patients aged 65 years or older and patients with renal impairment This medicine may be prescribed using the same dosage regimen as for patients aged 65 years or younger with normal renal function. * Patients at risk of hypoglycemia - Poor nutritional status or malnutrition - Severe or moderate compensated endocrine disorders (anterior pituitary insufficiency, hypothyroidism, corticotropin insufficiency) - Discontinuation of long-term and/or high-dose corticosteroid therapy - Severe vascular disease (severe coronary heart disease, severe carotid artery disease, diffuse vascular disease) → It is recommended to initiate treatment at the minimum dose of 30mg per day.

Ingredients

Manufacturer
(Samnam Pharmaceutical Co., Ltd.)

Efficacy & effects

Treatment of type 2 diabetes mellitus

  • Type 2 diabetes
View approved original text

This medication is used in patients with type 2 diabetes who have difficulty controlling blood sugar levels with diet and exercise alone. It helps effectively lower blood sugar levels and aids in blood sugar management. This can reduce the risk of complications and improve the overall health status of patients. Continuous use along with maintaining a healthy lifestyle is encouraged. This drug is very useful in the treatment of type 2 diabetes.

How to take

Adult dose

Adults: Start with 40~80mg of gliclazide per day, administered orally in 1~2 divided doses. Thereafter, to optimally control the patient's blood glucose level, the dose may be increased according to the patient's condition up to a maximum of 320mg per day, administered in 2 divided doses. Do not exceed 160mg per dose. The dose must be adjusted according to the patient's condition. Additional treatment may be required for obese patients or patients who do not respond adequately to this medicine alone. * Initial dose The recommended initial dose is 30mg per day. - If glycemic control is satisfactory, maintain this dose as the maintenance dose. - If glycemic control is unsatisfactory, the dose may be gradually increased to 60, 90, and 120mg per day at intervals of at least 1 month. If blood glucose has not decreased after 15 days of treatment, increase the dose from the end of the second week of treatment. Do not exceed the maximum dose of 120mg per day. * Switching from gliclazide 80mg to gliclazide modified-release tablets 30mg: In patients stabilized on gliclazide 80mg, administer the medicine according to the principle that "gliclazide 80mg = gliclazide modified-release tablets 30mg." * Switching from another oral hypoglycemic agent to gliclazide modified-release tablets 30mg: Consider the dose and half-life of the previous hypoglycemic agent. In general, switching can be done without any transitional washout period. Start this medicine at 30mg per day, then gradually increase the dose according to each patient's metabolic response as described in the "Initial dose" section. For patients switching from a sulfonylurea hypoglycemic agent with a long half-life, a washout period of several days is required to prevent the risk of hypoglycemia due to the additive effects of the two medicines. * Use in combination with other oral hypoglycemic agents This medicine may be used in combination with biguanides, α-glucosidase inhibitors, or insulin. * Patients aged 65 years or older and patients with renal impairment This medicine may be prescribed using the same dosage regimen as for patients aged 65 years or younger with normal renal function. * Patients at risk of hypoglycemia - Poor nutritional status or malnutrition - Severe or moderate compensated endocrine disorders (anterior pituitary insufficiency, hypothyroidism, corticotropin insufficiency) - Discontinuation of long-term and/or high-dose corticosteroid therapy - Severe vascular disease (severe coronary heart disease, severe carotid artery disease, diffuse vascular disease) → It is recommended to initiate treatment at the minimum dose of 30mg per day.

Precautions

This medication is a sulfonylurea and can cause hypoglycemia, so strict adherence to the dosage and administration is required. It should not be administered to patients with diabetic ketoacidosis, diabetic coma, patients with type 1 diabetes, or those with severe liver or kidney dysfunction, and is not recommended for patients with serious infections, trauma, or during pre-and post-operative periods. Patients who have reduced food intake due to diarrhea or vomiting, those who have had hypersensitivity reactions to this drug, pregnant or nursing women, patients taking miconazole, and those with lactose intolerance should not use this medication. Extra caution should be taken in elderly patients, those with impaired kidney and liver function, patients with endocrine disorders, those who are malnourished or have irregular eating habits, patients who exercise excessively or consume alcohol, and in cases where this drug is used in combination with other medications. This drug can cause hypoglycemic symptoms, including fatigue, hunger, tremors, headaches, confusion, dizziness, drowsiness, and convulsions, which in severe cases can lead to coma. Rarely, there may be changes in blood, liver dysfunction, gastrointestinal symptoms, skin rashes, and visual disturbances, so if any abnormal symptoms occur, it is essential to consult a doctor immediately. This medication is only used for patients with a confirmed diagnosis of diabetes and should be considered after adequate diet and exercise therapy have been ineffective. Start with a low dose and regularly check blood and urine sugar levels, and if insufficient effect is noted, other treatments can be considered. If hypoglycemia occurs, sugar should be ingested immediately, as artificial sweeteners are ineffective. Immediate medical attention is necessary if severe hypoglycemia is suspected. Blood sugar control can be affected by various factors such as infections, trauma, and surgery, so patients and their families should be informed about the symptoms of hypoglycemia, how to respond, and the importance of regular blood sugar monitoring. This drug may interact with specific medications; caution is needed when used in combination with miconazole, some anti-inflammatory drugs, alcohol, other diabetes medications, antibiotics, antidepressants, anticoagulants, etc. It should not be administered to pregnant or nursing women, and safety in children has not been established. Elderly patients have a higher risk of hypoglycemia due to decreased physical function, requiring regular monitoring. In cases of overdose, hypoglycemic symptoms may occur; mild cases can be managed with sugar intake, but severe cases require immediate treatment in a hospital. Care should be taken to avoid hypoglycemic symptoms when driving or operating machinery, especially in the early stages of treatment. This medication should be stored out of reach of children and not transferred to other containers for safety.

Side effects

  • hypoglycemia
  • weakness
  • intense hunger
  • tremors
  • headache
  • paresthesia
  • agitation
  • decreased concentration
  • aggressiveness
  • nausea
Show 55 more
  • vomiting
  • lethargy
  • sleep disturbances
  • decreased cognitive function
  • slow reactions
  • depression
  • confusion
  • visual impairment
  • speech disorders
  • aphasia
  • incomplete paralysis
  • dizziness
  • loss of self-control
  • delirium
  • shallow breathing
  • bradycardia
  • drowsiness
  • altered consciousness
  • convulsions
  • sweating
  • palpitations
  • cool and moist skin
  • anxiety
  • tachycardia
  • hypertension
  • angina
  • deep venous thrombosis
  • thrombocytopenia
  • anemia
  • leukopenia
  • agranulocytosis
  • aplastic anemia
  • liver dysfunction
  • hepatitis
  • jaundice
  • dyspepsia associated with vomiting
  • nausea
  • abdominal pain
  • diarrhea
  • constipation
  • itching
  • rash
  • urticaria
  • angioedema
  • erythema
  • large blister rash
  • measles-like papular rash
  • vesicular reaction
  • hemolytic anemia
  • pancytopenia
  • allergic vasculitis
  • hyponatremia
  • elevated liver enzyme levels
  • liver function impairment
  • liver failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering, and it is recommended to store it at room temperature between 1 to 30 degrees Celsius. This will help maintain the drug's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

White round tablets

Package unit

30 tablets/bottle, 500 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.